Evidence map›Paper›PMID 31653603›Full record

ReviewEpilepsy & behavior : E&B2019

Lessons from the Established Status Epilepticus Treatment Trial.

Hannah R Cock, Lisa D Coles, Jordan Elm, Robert Silbergleit, James M Chamberlain, James C Cloyd, Nathan Fountain, Shlomo Shinnar, Dan Lowenstein, Robin Conwit and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Epilepsy & behavior : E&B, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Treatment considerations for the management of neonatal onset seizures.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2025
    Article
  4. Review
  5. Strategies to innovate emergency care of status epilepticus.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Modeling current practices in critical care comparative effectiveness research.Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine · 2022
    Article
  10. A Theoretical Paradigm for Evaluating Risk-Benefit of Status Epilepticus Treatment.Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hannah R CockSt George's University of London and Atkinson Morley Regional Epilepsy Network, St George's University Hospitals NHS Foundation Trust, London, UK. Electronic address: hannahrc@sgul.ac.uk.
Lisa D ColesDepartment of Experimental and Clinical Pharmacology, College of Pharmacy and Center for Orphan Drug Research, University of Minnesota, Minneapolis, MN, USA.
Jordan ElmDepartment of Public Health Science, Medical University of South Carolina, Charleston, SC, USA.
Robert SilbergleitDepartment of Emergency Medicine, University of Michigan, Ann Arbor, MI, USA.
James M ChamberlainDivision of Emergency Medicine, Children's National Health System and the Department of Pediatrics and Emergency Medicine, School of Medicine and Health Sciences, George Washington University Washington, DC, USA.
James C CloydDepartment of Experimental and Clinical Pharmacology, College of Pharmacy and Center for Orphan Drug Research, University of Minnesota, Minneapolis, MN, USA.
Nathan FountainDepartment of Neurology (Fountain, Kapur), Brain Institute, University of Virginia, Charlottesville, VA, USA.
Shlomo ShinnarDepartments of Neurology, Pediatrics and Epidemiology and Population Health, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Dan LowensteinDepartment of Neurology, University of California, San Francisco, CA, USA.
Robin ConwitNational Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
Thomas P BleckDepartment of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Jaideep KapurDepartment of Neurology (Fountain, Kapur), Brain Institute, University of Virginia, Charlottesville, VA, USA; Department of Neuroscience (Kapur), Brain Institute, University of Virginia, Charlottesville, VA, USA.

Funding

Neurologic Emergencies Treatment Trials Network: Clinical Coordinating CenterU01NS056975 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BARSAN, WILLIAM G · 2006 to 2015
$40.4M
Established Status Epilepticus Treatment Trial (ESETT)U01NS088034 · NINDS · UNIVERSITY OF VIRGINIA · PI CHAMBERLAIN, JAMES, KAPUR, JAIDEEP · 2014 to 2018
$16.3M
Neurological Emergencies Treatment Trials Network Statistical and Data ManagementU01NS059041 · NINDS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI DURKALSKI, VALERIE L, PALESCH, YUKO Y · 2006 to 2015
$9.1M
Established Status Epilepticus Treatment Trial (ESETT) - SDMCU01NS088023 · NINDS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI ELM, JORDAN J. · 2014 to 2018
$2.0M
Accelerating Drug and Device Evaluation through Innovative Clinical Trial DesignU01NS073476 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BARSAN, WILLIAM G, BERRY, DONALD A · 2010 to 2012
$2.0M
ESETT Pharmacokinetic-Pharmacodynamic StudyR01NS099653 · NINDS · UNIVERSITY OF MINNESOTA · PI CLOYD, JAMES C., COLES, LISA D · 2017 to 2019
$1.0M
NINDS NIH HHS R01 NS099653NINDS NIH HHS U01 NS056975NINDS NIH HHS U01 NS059041NINDS NIH HHS U01 NS073476NINDS NIH HHS U01 NS088023NINDS NIH HHS U01 NS088034
6 · The paper itself

Abstract

Convulsive status epilepticus (SE) is a relatively common emergency condition affecting individuals of all ages. The primary goal of treatment is prompt termination of seizures. Where first-line treatment with benzodiazepine has failed to achieve this, a condition known as established SE (ESE), there is uncertainty about which agent to use next. The Established Status Epilepticus Treatment Trial (ESETT) is a 3-arm (valproate (VPA), fosphenytoin (FOS), levetiracetam (LEV)), phase III, double-blind randomized comparative effectiveness study in patients aged 2 years and above with established convulsive SE. Enrollment was completed in January 2019, and the results are expected later this year. We discuss lessons learnt during the conduct of the study in relation to the following: ethical considerations; trial design and practical implementation in emergency settings, including pediatric and adult populations; quality assurance; and outcome determination where treating emergency clinicians may lack specialist expertise. We consider that the ESETT is already informing both clinical practice and future trial design. This article is part of the Special Issue "Proceedings of the 7th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures".

Indexed as

AdultAnticonvulsantsBenzodiazepinesChild, PreschoolClinical Trials as TopicDiagnostic Tests, RoutineDouble-Blind MethodEmergency Service, HospitalFemaleHumansLevetiracetamMaleStatus EpilepticusTreatment OutcomeValproic AcidAnticonvulsantsBenzodiazepinesLevetiracetamValproic AcidClinical trialLevetiracetamMethodologyPhenytoinStatus epilepticusValproate

Identifiers

PMID31653603
PMCPMC6944752

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.